摘要
目的探究HBeAg阳性慢乙肝(慢性乙型肝炎)患者的临床表现及恩替卡韦的疗效。方法随机抽取2015年1月至2017年12月我院100例慢性乙型肝炎患者为观察对象,结合HBeAg检测结果将其分为阳性组(68例)、阴性组(32例)。对比两组患者的临床表现。对HBeAg阳性慢乙肝患者均实施恩替卡韦治疗,均随访6个月,分析恩替卡韦的疗效。结果①HBeAg阳性组患者的平均年龄较阴性组患者更低,但HBV-DNA较阴性组更高,P<0.05,而ALT、ALB值无显著差异,P>0.05;②经恩替卡韦治疗半年后,32例患者HBV-DNA水平完全抑制,24例患者HBV-DNA水平部分抑制,12例患者不抑制,总抑制率为82.35%;HBeAg转阴率为41.18%、肝功能指标复常率为73.53%、血病毒转阴率为29.41%、粒细胞降低率为4.41%。结论相比于HBeAg阴性慢乙肝患者,HBeAg阳性患者的年龄更小,HBV-DNA定量水平更高。对HBeAg阳性慢乙肝患者实施恩替卡韦治疗具有一定的抗病毒效果,对控制病情具有较积极的意义。
Objective To investigate the clinical manifestations of patients with HBeAg-positive chronic hepatitis B(chronic hepatitis B) and the efficacy of entecavir. Methods One hundred patients with chronic hepatitis B in our hospital from January 2015 to December 2017 were randomly selected. The results were divided into positive group(68 cases) and negative group(32 cases) according to the results of HBeAg test. The clinical manifestations of the two groups of patients were compared. Entecavir was performed in patients with HBeAg-positive chronic hepatitis B.All patients were followed up for 6 months to analyze the efficacy of entecavir. Results Firstly, the average age of patients with HBeAg positive group was lower than that of the negative group, but HBV-DNA was higher than that of the negative group, P<0.05, but there was no significant difference in ALT and ALB values, P>0.05. Secondly, after entecavir treatment for half a year, HBV-DNA levels were completely inhibited in 32 patients, HBV-DNA levels were partially inhibited in 24 patients, and 12 patients were not inhibited. The total inhibition rate was 82.35%;the HBeAg negative rate was 41.18%, and the liver function index was 73.53%. The blood virus conversion rate was 29.41%, and the granulocyte reduction rate was 4.41%. Conclusion Compared with HBeAg-negative chronic hepatitis B patients,HBeAg-positive patients are younger and have higher levels of HBV-DNA quantification. The treatment of entecavir in patients with HBeAg-positive chronic hepatitis B has a certain antiviral effect and has a positive effect on the control of the disease.
作者
邓小艳
DENG Xiao-yan(Linyi Third People's Hospital,Linyi,Shanxi,041000)
出处
《智慧健康》
2019年第6期80-81,共2页
Smart Healthcare
